Drug Prices

Drug Prices
Pharmalot

U.S. spending on prescription drugs rose less than 1 percent last year

By Ed Silverman

Pharmalot

Pharmalittle: Amgen migraine drug show promise; DEA moves to tighten opioid rules

By Ed Silverman

Pharmalot

Pharmalittle: Sanofi warns Canada over industry treatment; Pfizer got a big boost from the new tax law

By Ed Silverman

Gilead Sciences
Pharmalot

Will this experimental hepatitis C treatment break Gilead’s grip on middle-income countries?

By Ed Silverman

NIH headquarters
Pharmalot

NIH is urged to probe Aegerion patents for failing to disclose federal funding

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer paid its CEO how much? Glaxo says Brexit will not be cheap

By Ed Silverman

Clogged Artery
Biotech

Wall Street reacts to Regeneron, Sanofi cholesterol drug study results

By Adam Feuerstein and Damian Garde

Martin Shkreli & Benjamin Brafman
Adam's Take

Martin Shkreli has been sentenced. The drug industry is trying to get away scot-free

By Adam Feuerstein

Pricey Drugs
Pharmalot

UnitedHealthcare will pass some rebates to consumers, but will this really lower drug prices?

By Ed Silverman

Anthony Anex/Keystone via AP
Pharmalot

Advocates protest Novartis ‘bullying tactics’ over access to medicines in poor countries

By Ed Silverman

Len Schleifer
Pharmalot

Despite ‘responsible’ price, Regeneron drug kept out of many patients’ hands by payers

By Ed Silverman

Adam's Take

Acadia Pharma raised the price of its only drug twice but quarterly sales still disappoint

By Adam Feuerstein

Merck logo
Pharmalot

A reversal of fortunes: Judge voids order Gilead must pay $2.5B to Merck over a patent dispute

By Ed Silverman

John McCain- Glioblastoma
Pharmalot

McCain and Baldwin to Trump: Hold pharma’s feet to the fire on drug prices

By Ed Silverman

Pharmalot

Pharmalittle: Supermarkets sue over generic price fixing; Daiichi can collect that $550 million award

By Ed Silverman

Drug Discount Program
Pharmalot

Drug makers are offering bigger discounts than ever before

By Ed Silverman

Pharmalot

Pharmalittle: J&J slams U.K. cost-effectiveness watchdog; U.S. fights U.N. access plan

By Ed Silverman

Pharmalot

Pharmalittle: Judge wants to settle opioid suits quickly; Glaxo eyes Pfizer consumer biz

By Ed Silverman

Three vials
Business

Spark prices its gene therapy as most expensive U.S. medicine — but with plans to ease cost concerns

By Adam Feuerstein and Damian Garde

CAR-T
Pharmalot

Those high-priced CAR-T therapies are actually cost effective

By Ed Silverman

Susan Collins
Pharmalot

Lawmakers demand answers on a huge price hike for an old drug

By Ed Silverman

Pharmalot

Pharmalittle: PhRMA collects more cash; McKesson under fire in Canada

By Ed Silverman

Pharmalot
Pharmalot

Pharma sues California over its new transparency law for drug pricing

By Ed Silverman

Politics

Obamacare? That’s so last month. On Capitol Hill, drug prices are now the hot topic

By Erin Mershon

Pharmalot
Pharmalot

Not a Dutch treat: Drug prices prompt debate over ‘last resort’ options in Amsterdam

By Ed Silverman

Ohio Election 2017
Politics

Ohio voters reject measure to rein in drug costs

By Casey Ross

Pharmalot

Pharmalittle: Novo blasts U.S. transparency bills; House hearing set for patents and sovereign immunity

By Ed Silverman

Steven Pearson drug prices
Pharmalot

Pharma cost watchdog, with fresh backing, will issue reports on ‘unjustified price hikes’

By Ed Silverman

Harvoni
Business

Gilead’s hepatitis C business is still shrinking and investors are freaking out

By Adam Feuerstein

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.